Abstract
Purpose We aimed to assess the effect of hemoglobin (Hb) concentration and oxygenation index on COVID-19 patients’ mortality risk.
Patients and methods We retrospectively reviewed sociodemographic and clinical characteristics, laboratory findings, and clinical outcomes from patients admitted to a tertiary care hospital in Bogotá, Colombia. We assessed exploratory associations between oxygenation index and Hb concentration at admission and clinical outcomes. We used a generalized additive model (GAM) to evaluate the nonlinear relations observed and the classification and regression trees (CART) algorithm to assess the interaction effects found.
Results From March to July 2020, 643 patients were admitted, of which 52% were male. The median age was 60 years old, and the most frequent comorbidity was hypertension (35.76%). The median value of SpO2/FiO2 was 419, and the median Hb concentration was 14.8 g/dL. The mortality was 19.1% (123 patients). Age, sex, and history of hypertension were independently associated with mortality. We described a nonlinear relationship between SpO2/FiO2, Hb concentration and neutrophil-to-lymphocyte ratio with mortality and an interaction effect between SpO2/FiO2 and Hb concentration. Patients with a similar oxygenation index had different mortality likelihoods based upon their Hb at admission. CART showed that patients with SpO2/FiO2 < 324, who were older than 62 years, and had an Hb of ≥ 16 g/dl had the highest mortality risk (96%). Additionally, patients with SpO2/FiO2 > 324 but Hb of < 12 and neutrophil-to-lymphocyte ratio of > 4 had a higher mortality likelihood (57%). In contrast, patients with SpO2/FiO2 > 324 and Hb of > 12 g/dl had the lowest mortality risk (10%).
Conclusion We found that a decreased SpO2/FiO2 increased mortality risk. Extreme values of Hb, either low or high, showed an increase in likelihood of mortality. However, Hb concentration modified the SpO2/FiO2 effect on mortality; the likelihood of death in patients with low SpO2/FiO2 increased as Hb increased.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Rosario University's ethics committee. The approval number is DVO005 1578-CV1411. The informed consent was obtained in written form.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
Abbreviations
- AIC
- Akaike information criteria
- ALC
- Absolute lymphocyte count
- ANC
- Absolute neutrophil count
- ARDS
- Acute respiratory distress syndrome
- BMI
- Body mass index
- CART
- Classification and regression tree
- CBC
- Complete blood count
- CKD
- Chronic kidney disease
- CMS
- Chronic mountain sickness
- COPD
- Chronic obstructive pulmonary disease
- EPO
- Erythropoietin
- FiO2
- Fraction inspired
- O2; GAM
- Generalized additive model
- Hb
- Hemoglobin concentration (g/dL)
- HIF-1a
- Hypoxia-inducible factor 1-α
- HIV
- Human immunodeficiency virus
- HUM
- Hospital Universitario Mayor
- MAP
- Mean arterial pressure
- MASL
- Meters above sea level
- NK
- Natural killer cells
- NLR
- Neutrophil to lymphocyte ratio
- NRBCs
- Nucleated red blood cells circulating
- PCO2
- Partial CO2 pressure
- RBC
- Red blood cells count
- RDW
- Red blood cell distribution width
- SpO2
- Peripheral O2 saturation
- VEGF
- Vascular-endothelial growth factor
- WBC
- White blood cell count
- WMD
- Weighted mean difference.